ACTRN12607000104459已完成4 期
Rituximab in the adjuvant treatment of bullous pemphigoid: a prospective open-label pilot study in three patients to study remission of disease with rituximab
Peter MacCallum Cancer Centre0 个研究点目标入组 3 人开始时间: 2007年2月2日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 16 Years 至 o limit（—）
- 性别
- All
入选标准
- •No severe infection requiring systemic antibiotics, failed to respond to systemic steroids or requiring doses of >10mg prednisolone per day or requiring systemic immunosuppression or unable to tolerate oral steroids.
排除标准
- •WHO performance status >3, unable to comprehend patient information and consent form.
研究者
相似试验
已完成
1 期
Rituximab in the Treatment of Patients With Bullous PemphigoidBullous PemphigoidNCT00286325Duke University8
进行中（未招募）
1 期
Will a single dose of Rituximab treatment, when taken with anti thyroid drugs for 1 year, stop the over-activity of the thyroid gland from returning once you stop ATD treatment?EUCTR2016-000209-35-GBewcastle upon Tyne Hospitals NHS Foundation Trust27
已完成
2 期
The efficacy of rituximab for recalcitrant Pemphigus Vulgaris in the patients of Razi hospital from 2007 to 2011Pemphigus vulgaris.Pemphigus vulgarisIRCT201111022704N2Vice-chancellor for Research of Tehran University of Medical Sciences40
进行中（未招募）
不适用
Rituximab plus Bendamustine as front line treatment in frail elderly (=70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi (FIL)EUCTR2011-001421-24-ITFONDAZIONE ITALIANA LINFOMI ONLUS
招募中
不适用
Adjuvant therapy of severe and/or refractory bullous pemphigoids with immunoadsorption by LIGASORB®, dapsone, prednisolone and topical mometasone fumarate (LiBPem-Study).L12.0Bullous pemphigoidDRKS00013775niversitätsklinikum Schleswig-Holstein Campus Lübeck10